Eco Animal Health Group PLC Investor Presentation covering Interim Results

TIDMEAH

Eco Animal Health Group PLC

22 November 2022

ECO Animal Health Group plc

("ECO" or the "Group") (AIM: EAH)

Investor Presentation covering Interim Results

ECO Animal Health Group plc, a leader in the development, registration and marketing of pharmaceutical products for global animal health markets, is pleased to announce that David Hallas, CEO, and Christopher Wilks, CFO, will be conducting a live presentation covering the Group's interim results for the period ended 30 September 2022.

The online presentation will take place on Monday 28 November at 10.00 am UK time. This event is open to all existing and potential shareholders and registration is free. Questions can be submitted during the presentation and will be addressed at the end of it.

   To register for the event, please   click here 
   A video recording of the presentation will be available shortly afterwards   here 

Contacts:

 
 ECO Animal Health Group plc 
  David Hallas (CEO) 
  Christopher Wilks (CFO)                      020 8447 8899 
 IFC Advisory 
  Graham Herring 
  Zach Cohen                                  020 3934 6630 
 Singer Capital Markets (Nominated Adviser 
  & Joint Broker) 
  Mark Taylor 
  George Tzimas                               020 7496 3000 
 Investec (Joint Broker) 
  Gary Clarence 
  Daniel Adams 
  Carlo Spingardi                             020 7597 5970 
 Peel Hunt LLP (Joint Broker) 
  Dr Christopher Golden 
  James Steel                                 020 7418 8900 
 Equity Development 
  Hannah Crowe 
  Matt Evans                                  020 7065 2692 
 

About ECO Animal Health

ECO Animal Health Group plc researches, develops and commercialises products for livestock. Our business strategy is to generate shareholder value by achieving the maximum sales potential from the existing product portfolio whilst investing in Research and Development ("R&D") for new products, particularly vaccines, and seeking to in-license new products

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word "Reach" in the source column of the News Explorer pages of London Stock Exchange's website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NRABRBDBISDDGDB

(END) Dow Jones Newswires

November 22, 2022 02:00 ET (07:00 GMT)